Cluster of Differentiation 36-Mediated Inflammation and Lipid Metabolism in Cardiovascular Diseases: From Mechanisms to Novel Therapies
Antioxidants · 30.05.2026 · 15 (6) · 694
DOI: 10.3390/antiox15060694 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 30.05.2026. Verfasst von Jiayin Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China. Die Arbeit nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jiangxi Province, Health Commission of Jiangxi province, the Jiangxi Province Key Laboratory of bioengineering drugs.
Abstract (Originalsprache)
Cardiovascular diseases (CVDs) continue to pose a key challenge to public health because of their high prevalence, mortality, and disability rates, together with a trend toward younger age at onset. Chronic inflammation and disordered lipid metabolism are key pathological mechanisms underlying the development and progression of CVDs. Although numerous pharmacological agents have been developed to intervene in CVDs, current therapies are still limited by adverse effects, suboptimal efficacy, and insufficient anti-inflammatory properties. Consequently, effective drug-based strategies for the prevention and treatment of certain CVDs are still insufficient. Cluster of differentiation 36 (CD36), a class B scavenger receptor, mediates the recognition and uptake of long-chain fatty acids, oxidized low-density lipoprotein, and other ligands, and is present in diverse tissues and cell types. Accumulating evidence indicates that CD36 plays a critical role in lipid metabolism and inflammatory signalling pathways implicated in CVDs, suggesting that it represents a promising focus for treatment-oriented interventions. This review synthesizes current evidence on the multifaceted roles of CD36 in lipid metabolism dysregulation and inflammation-associated pathways in CVDs and evaluates its potential as a tractable target for disease prevention and management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
- Jiangxi Province Key Laboratory of Bioengineering Drugs, The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang Uni…
- Institute of Biomedical Innovation, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
Förderung
- Natural Science Foundation of Jiangxi Province
- Health Commission of Jiangxi province
- the Jiangxi Province Key Laboratory of bioengineering drugs
- Jiangxi Province Key Laboratory of Bioengineering Drugs
Zitieren
APA
Song, J., Han, X., Zhang, Y., & Jiang, M. (2026). Cluster of Differentiation 36-Mediated Inflammation and Lipid Metabolism in Cardiovascular Diseases: From Mechanisms to Novel Therapies. Antioxidants, 15(6), 694. https://doi.org/10.3390/antiox15060694
Vancouver
Song J, Han X, Zhang Y, Jiang M. Cluster of Differentiation 36-Mediated Inflammation and Lipid Metabolism in Cardiovascular Diseases: From Mechanisms to Novel Therapies. Antioxidants. 2026;15(6):694. doi:10.3390/antiox15060694
BibTeX
@article{Song2026,
author = {Song, Jiayin and Han, Xiangnuo and Zhang, Yu and Jiang, Meixiu},
title = {Cluster of Differentiation 36-Mediated Inflammation and Lipid Metabolism in Cardiovascular Diseases: From Mechanisms to Novel Therapies},
journal = {Antioxidants},
year = {2026},
volume = {15},
number = {6},
pages = {694},
doi = {10.3390/antiox15060694}
}
EUVIMED